194 related articles for article (PubMed ID: 34224666)
1. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
Kamboj M
Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
[No Abstract] [Full Text] [Related]
2. COVID-19 vaccines for patients with haematological conditions.
Sun C; Pleyer C; Wiestner A
Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
[No Abstract] [Full Text] [Related]
3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
4. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
[No Abstract] [Full Text] [Related]
5. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
6. Messenger RNA vaccines against SARS-CoV-2.
Topol EJ
Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
[TBL] [Abstract][Full Text] [Related]
7. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.
Redjoul R; Le Bouter A; Parinet V; Fourati S; Maury S
Lancet Haematol; 2021 Oct; 8(10):e681-e683. PubMed ID: 34487683
[No Abstract] [Full Text] [Related]
8. Safety of mRNA-Based Vaccines for SARS CoV-2.
Barda B; Cerny A
Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 may become nanomedicine's finest hour yet.
Friedrichs S; Bowman DM
Nat Nanotechnol; 2021 Apr; 16(4):362-364. PubMed ID: 33854220
[No Abstract] [Full Text] [Related]
10. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
[TBL] [Abstract][Full Text] [Related]
11. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.
Lombardi A; Bozzi G; Ungaro R; Villa S; Castelli V; Mangioni D; Muscatello A; Gori A; Bandera A
Front Immunol; 2021; 12():657711. PubMed ID: 33777055
[No Abstract] [Full Text] [Related]
12. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.
Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
Front Immunol; 2021; 12():679344. PubMed ID: 34305909
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
[TBL] [Abstract][Full Text] [Related]
14. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.
Sesques P; Bachy E; Ferrant E; Safar V; Gossez M; Morfin-Sherpa F; Venet F; Ader F
Cancer Cell; 2022 Mar; 40(3):236-237. PubMed ID: 35093212
[No Abstract] [Full Text] [Related]
15. Innovators target vaccines for variants and shortages in global South.
Sheridan C
Nat Biotechnol; 2021 Apr; 39(4):393-396. PubMed ID: 33731936
[No Abstract] [Full Text] [Related]
16. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Cattaneo C; Cancelli V; Imberti L; Dobbs K; Sottini A; Pagani C; Belotti A; Re A; Anastasia A; Quaresima V; Tucci A; Chiorini JA; Su HC; Cohen JI; Burbelo PD; Rossi G; Notarangelo LD
Blood Cancer J; 2021 Sep; 11(9):151. PubMed ID: 34521813
[TBL] [Abstract][Full Text] [Related]
17. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.
Sui Y; Li J; Zhang R; Prabhu SK; Andersen H; Venzon D; Cook A; Brown R; Teow E; Velasco J; Greenhouse J; Putman-Taylor T; Campbell TA; Pessaint L; Moore IN; Lagenaur L; Talton J; Breed MW; Kramer J; Bock KW; Minai M; Nagata BM; Lewis MG; Wang LX; Berzofsky JA
JCI Insight; 2021 Apr; 6(10):. PubMed ID: 33908897
[TBL] [Abstract][Full Text] [Related]
18. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination.
Lippi G; Sciacovelli L; Trenti T; Plebani M;
Clin Chem Lab Med; 2021 Jul; 59(8):1333-1335. PubMed ID: 33578505
[No Abstract] [Full Text] [Related]
20. [Vaccination immunology in SARS-CoV-2].
Helweg-Larsen J; Benfield T
Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
